Wilmer Cutler Pickering Hale and Dorr has advised Hemab Therapeutics Holdings, Inc. Goodwin Procter has advised the underwriters. Hemab Therapeutics Holdings, Inc., a clinical-stage biotechnology company,...
Hemab Therapeutics Closes Upsized Initial Public Offering on Nasdaq
Climb Bio Completes $110 Million Private Placement
Wilmer Cutler Pickering Hale and Dorr has advised Climb Bio, Inc. on the deal. Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company, has announced the...